Clinical trial
Open Label Study of a Single Dose of a New Extended Long Acting Formulation of…
NCT00432068 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00432068 |
|---|---|
| Title | Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers |
| Official title | A Phase I , Open Label, Single Center, Dose Escalation Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of a New Extended Long-acting Formulation of Octreotide Pamoate Administered i.m. in Healthy Cholecystectomized Volunteers |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy Cholecystectomized |
| Intervention type | Drug |
| Interventions | Octreotide pamoate |
| Enrollment | 48 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Feb 6, 2007 |
| Last update posted | Dec 3, 2015 |
| Countries | Belgium, France, Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: